{"id":"act-539313","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL6068504","moleculeType":"Small molecule","molecularWeight":"545.72"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ACT-539313 works by blocking the action of dopamine at the D2 receptor, which is involved in various physiological processes including movement and mood regulation. This blockade is thought to contribute to its therapeutic effects.","oneSentence":"ACT-539313 is a selective dopamine D2 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:47.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant schizophrenia"}]},"trialDetails":[{"nctId":"NCT04753164","phase":"PHASE2","title":"Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2021-02-16","conditions":"Binge-Eating Disorder","enrollment":136},{"nctId":"NCT05254548","phase":"PHASE1","title":"A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2022-02-18","conditions":"Healthy","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACT-539313","genericName":"ACT-539313","companyName":"Idorsia Pharmaceuticals Ltd.","companyId":"idorsia-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACT-539313 is a selective dopamine D2 receptor antagonist. Used for Treatment-resistant schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}